Novartis has developed an experimental drug which is borne by several researchers since it demonstrated incredible results.
The trial treatment generally known as LCZ6696 slower down the hazards of cardiovascular deaths and admissions to health with a great number.
Milton Packer of University of Texas stated that it would be useless for doctors to prescribe the traditional medicines shortly after the availability of this drug. Moreover, he said that the outcome of this study is really amazing.
The researchers have failed to develop anything constructive in the arena of chronic heart disease. In this disease heart is unable to pump enough blood all around the body. Therefore, both the doctors and investors are quite enthusiastic about this medication.
This study also compared this drug to the older one which are usually urged by the doctors for this ailment. The researchers halted the study in the middle because the result of LCZ696 was really astonishing. However, the researchers revealed this news on Saturday at the annual meeting of the European Society of Cardiology (ESC). This conference is regarded as the world’s biggest cardiology congress.
ESC authorities marked the PARADIGM-HF experiment as the main discussion during the entire five day event.
Novartis is hopeful that this new drug will revitalize the wealth of the company. The data of this product is viewed as the most significant catalyst for the stock.
David Epstein, the company’s pharmaceutical head stated that the result of this drug is way better than what researchers have accepted.
The second most notable benefit of this drug is that it made patients feel evidently better.